Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells
- 427 Downloads
Exosomes are the best options for gene targeting, because of their natural, nontoxic, non-immunogenic, biodegradable, and targetable properties. By engineering exosome-producing cells, ligands can be expressed fusing with exosomal surface proteins for targeting cancer cell receptors. In the present study, HER2-positive breast cancer cells were targeted with a modified exosome producing engineered HEK293T cell. For this purpose, the HEK293T cells were transduced by a lentiviral vector bearing-LAMP2b-DARPin G3 chimeric gene. Stable cells expressing the fusion protein were selected, and the exosomes produced by these cells were isolated from the culture medium, characterized, and then loaded with siRNA for subsequent delivery to the SKBR3 cells. Our results showed that stable HEK293T cells produced DARPin G3 on the surface of exosomes. These exosomes can bind specifically to HER2/Neu and are capable of delivering siRNA molecules against TPD52 gene into SKBR3 cell line down-regulating the gene expression up to 70%. Present approach is envisaged to facilitate genes and drugs transfer to HER2 cancer cells providing additional option for gene therapy and drug delivery.
KeywordsExosome HER2 siRNA delivery TPD52 Lentiviral vector
This work was supported by educational program grant from Tarbiat Modares University and Iranian national science foundation: INSF (code No: 90006884).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., Lin, C., Leach, C., Cannady, R. S., Cho, H., Scoppa, S., Hachey, M., Kirch, R., Jemal, A., & Ward, E. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241.Google Scholar
- 4.Wahlgren J, Karlson TDL, Brisslert M, Sani FV, Telemo E, Sunnerhagen P, et al. (2012). Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Research, 40(17), e130. https://doi.org/10.1093/nar/gks463.
- 10.Tan, A., De La Peña, H., & Seifalian, A. M. (2010). The application of exosomes as a nanoscale cancer vaccine. International Journal of Nanomedicine, 5, 889.Google Scholar
- 17.Khodashenas Limoni, S., Salimi, F., & Forouzandeh Moghaddam, M. (2017). Designing pLEX-LAMP-DARPin lentiviral vector for Exression of HER2 targeted DARPin on exosome surface. Journal of Mazandaran University of Medical. Sciences, 27(151), 12–23.Google Scholar
- 19.Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocols in Cell Biology, 3(22), 1–3. 9.Google Scholar
- 22.Li, J., Chen, X., Yi, J., Liu, Y., Li, D., Wang, J., Hou, D., Jiang, X., Zhang, J., Wang, J., Zen, K., Yang, F., Zhang, C. Y., & Zhang, Y. (2016). Identification and characterization of 293T cell-derived exosomes by profiling the protein, mRNA and microRNA components. PLoS One., 11(9), e0163043.CrossRefGoogle Scholar
- 24.Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., & Pluckthun, A. (2010). Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Research, 70(4), 1595–1605.CrossRefGoogle Scholar
- 26.Zeelenberg, I. S., Ostrowski, M., Krumeich, S., Bobrie, A., Jancic, C., Boissonnas, A., Delcayre, A., le Pecq, J. B., Combadiere, B., Amigorena, S., & Thery, C. (2008). Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Research, 68(4), 1228–1235.CrossRefGoogle Scholar
- 29.Konecki, D. S., Foetisch, K., Zimmer, K.-P., Schlotter, M., & Konecki, U. L. (1995). An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochemical and Biophysical Research Communications, 215(2), 757–767.CrossRefGoogle Scholar
- 30.Sambrook, J., Fritsch, E. F., & Maniatis, T. (1989). Molecular cloning. New York: Cold spring harbor laboratory press.Google Scholar
- 35.Roslan N. (2013). PhD thesis, Inhibiting tumor protein D52 function for anti-cancer therapy application. Sydney: University of Sydney.Google Scholar